Spencer Van Decar
Overview
Explore the profile of Spencer Van Decar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
7
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tiwari A, Alcover K, Carpenter E, Thomas K, Krum J, Nissen A, et al.
Hum Vaccin Immunother
. 2024 Mar;
20(1):2323256.
PMID: 38544385
Cell-based therapeutic cancer vaccines use autologous patient-derived tumor cells, allogeneic cancer cell lines or autologous antigen presenting cells to mimic the natural immune process and stimulate an adaptive immune response...
2.
Valdera F, OShea A, Smolinsky T, Carpenter E, Adams A, McCarthy P, et al.
J Surg Oncol
. 2023 Oct;
129(2):244-253.
PMID: 37800378
Introduction: Adjuvant (A) multiagent chemotherapy (MC) is the standard of care for patients with pancreatic adenocarcinoma (PDAC). Tolerating MC following a morbid operation may be difficult, thus neoadjuvant (NA) treatment...
3.
Carpenter E, Van Decar S, Adams A, OShea A, McCarthy P, Chick R, et al.
J Immunother Cancer
. 2023 Aug;
11(8).
PMID: 37536936
Background: The tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is made by ex vivo priming matured autologous dendritic cells (DCs) with yeast cell wall particles (YCWPs) loaded with autologous tumor...
4.
McCarthy P, Valdera F, Smolinsky T, Adams A, OShea A, Thomas K, et al.
Front Immunol
. 2023 Mar;
14:1090533.
PMID: 36960052
Checkpoint inhibitors have invigorated cancer immunotherapy research, including cancer vaccination. Classic early phase trial design and endpoints used in developing chemotherapy are not suited for evaluating all forms of cancer...